Anshu Gupta, MD
Plastic Surgery · Encinitas, CANPI 1184882904
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.0%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Stryker at 55.8% of the total. Reporting peaked in 2019 at $6,035 and has fallen 66.9% since, to $1,998 in 2025.
Across 92 payments — averaging $142.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$7K
- Sientra, Inc.$3K
- Renerve Ltd$2K
- TELA Bio, Inc.$457
- Motiva USA, LLC$280
- RTI Surgical, Inc$164
- plus $532 from 8 others
Across 19 payments — averaging $35,221 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mentor Worldwide LLC$669K
What the payments were for
- Consulting fees$6,03546%
- Travel & lodging$6265%
- Food & beverage$4,70536%
- Education$110%
- Gifts$1,75013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker(2 entities) | 22 | $7,325 |
| Sientra, Inc. | 35 | $2,619 |
| Renerve Ltd | 1 | $1,750 |
| TELA Bio, Inc. | 8 | $457 |
| Motiva USA, LLC | 4 | $280 |
| RTI Surgical, Inc | 1 | $164 |
| Mentor Worldwide LLC | 4 | $127 |
| AbbVie(2 entities) | 4 | $102 |
| Galderma Laboratories, L.p. | 4 | $84 |
| Davol Inc. | 3 | $69 |
| Pacira Pharmaceuticals Incorporated | 3 | $65 |
| Merz North America, Inc. | 1 | $34 |
| Kerecis Limited | 1 | $32 |
| Novo Nordisk | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,128 in reported general payments places this provider in the 85th percentile of 780 plastic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 56 | $398 |
| Ketorolac Tromethamine | 27 | $348 |
| Ondansetron OdtOndansetron | 47 | $198 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 52 | $146 |
| Cephalexin | 28 | $119 |
| Ibuprofen | 15 | $60 |
Paid to pharmacies, not to this prescriber.
Other plastic surgery in Encinitas
- Rahm NazeraliPalo Alto$1.5M
- Vipul DevBakersfield$1.1M
- Arash MomeniPalo Alto$836K
- Anne PeledSan Francisco$570K
- Salvatore PacellaSan Diego$517K
- Hani SbitanySan Francisco$510K
- John ApostolidesSan Diego$460K
- Garrett WirthNewport Beach$362K
- Michael BainNewport Beach$341K
- Joshua KormanMountain View$335K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.